Overview

Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the long-term, safety of Methylphenidate Transdermal System (MTS) in aged 13-17 years diagnosed withADHD
Phase:
Phase 3
Details
Lead Sponsor:
Noven Therapeutics
Treatments:
Methylphenidate